Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

Category: Medmonitor

November 15, 2024
Imuldosa Approved as Stelara® Biosimilar

This drug has been approved for the treatment of multiple chronic inflammatory disorders.

READ MORE
October 24, 2024
FDA Considers Policy Changes for GLP-1 Compounds

Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.

READ MORE
September 24, 2024
FDA Approves Zurnai and Neffy

FDA Approves Zurnai and Neffy

READ MORE
August 23, 2024
Recalls and Alerts Impacting Workers’ Comp

The FDA issued notices for certain migraine, acetaminophen, clonazepam, and semaglutide products.

READ MORE
May 20, 2024
Rezenopy Approved for Treatment of Opioid Overdose

A new naloxone nasal spray will soon be available.

READ MORE
April 24, 2024
Lot of Methocarbamol Recalled Due to White Particles

Patients taking this muscle relaxant may be impacted by a lot from Eugia US/AuroMedics Pharma.

READ MORE
April 23, 2024
Cardiovascular Drug Approvals

As firefighters see more presumptions for heart disease, keeping track of heart medications could grow in importance.

READ MORE
March 21, 2024
New Autoimmune Biosimilar Approved and Alzheimer’s Drug Goes Generic

Simlandi injection was approved for arthritic conditions, while Namzaric receives its first generic approval.

READ MORE
February 21, 2024
FDA Evaluates Report of Suicidal Thoughts with GLP-1 Receptor Agonist

While no clear link is established to these obesity and diabetes drugs, the FDA will continue to monitor data.

READ MORE
January 17, 2024
FDA Issues Respective Warnings for Compounded and Counterfeit Semaglutide

The growing demand for this drug has led individuals to search for semaglutide from alternative sources.

READ MORE
1 2 3 8
lockenvelopephone-handsetmagnifiermenucross-circle